J
Jürgen Scheele
Researcher at Merck KGaA
Publications - 24
Citations - 721
Jürgen Scheele is an academic researcher from Merck KGaA. The author has contributed to research in topics: non-small cell lung cancer (NSCLC) & Gefitinib. The author has an hindex of 7, co-authored 24 publications receiving 336 citations. Previous affiliations of Jürgen Scheele include University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik,E. Felip,Remi Veillon,Hiroshi Sakai,Alexis B. Cortot,Marina Chiara Garassino,J. Mazieres,Santiago Viteri,Hélène Senellart,Jan van Meerbeeck,Jo Raskin,Niels Reinmuth,Pierfranco Conte,Dariusz M. Kowalski,Byoung Chul Cho,Jyoti D. Patel,Leora Horn,Frank Griesinger,Ji Youn Han,Young Chul Kim,Gee Chen Chang,Chen Liang Tsai,James Chih-Hsin Yang,Yuh Min Chen,Egbert F. Smit,Anthonie J. van der Wekken,Terufumi Kato,Dilafruz Juraeva,Christopher Stroh,Rolf Bruns,J. Straub,Andreas Johne,Jürgen Scheele,J. Heymach,Xiuning Le +34 more
TL;DR: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients, and adverse events led to permanent discontinuation of tEPotinib in 11% of the patients.
Journal ArticleDOI
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Yi-Long Wu,Ying Cheng,Jianying Zhou,Shun Lu,Yiping Zhang,Jun Zhao,Dong Wan Kim,Ross A. Soo,Sang-We Kim,Hongming Pan,Yuh Min Chen,Chih-Feng Chian,Xiaoqing Liu,Daniel Shao Weng Tan,Rolf Bruns,J. Straub,Andreas Johne,Jürgen Scheele,Keunchil Park,James Chih-Hsin Yang,Zhe Liu,Xi Chen,Mengzhao Wang,Shiying Yu,Helong Zhang,Jian Fang,Wei Li,Chih-Hsin Yang,Gee-Chen Chang,Te Chun Hsia,Cheng-Ta Yang,Chin-Chou Wang,Byoung Chul Cho,Ki Hyeong Lee,Young-Chul Kim,Ho Jung An,In Sook Woo,Jae Yong Cho,Sang Won Shin,Jongmin Lee,Joo Hang Kim,Seung Soo Yoo,Terufumi Kato,Naofumi Shinagawa,Shao Weng Daniel Tan,Lynette Si-Mien Ngo,Kananathan Ratnavelu,Azura Rozila Ahmad,Chong-Kin Liam,Filippo de Marinis,Pierfrancesco Tassone,Amelia Insa Molla,Antonio Calles Blanco,Martin Emilio Lazaro Quintela,Enriqueta Felip Font,Anne-Marie C. Dingemans,Lynne Bui +56 more
TL;DR: Survival outcomes were similar between groups, and patients with EGFR-mutant, T790M-negative NSCLC MET overexpression or MET amplification had acquired resistance to EGFR inhibition, so tepotinib 500 mg was used as the recommended phase 2 dose.
Journal ArticleDOI
Phase II study of tepotinib in NSCLC patients with METex14 mutations.
Paul K. Paik,Remi Veillon,Alexis B. Cortot,Enriqueta Felip,Hiroshi Sakai,Julien Mazieres,Frank Griesinger,Leora Horn,Hélène Senellart,Jan P. van Meerbeeck,Javier de Castro Carpeño,Jyoti D. Patel,Marina Chiara Garassino,Masahiro Morise,Niels Reinmuth,Santiago Viteri,Takaaki Tokito,Tomohiro Sakamoto,Jürgen Scheele,Xiuning Le +19 more
TL;DR: MET exon 14 skipping mutations - reported in 3~4% of NSCLC patients (pts) - are activating, sensitive to MET inhibition and can be conveniently detected using liquid biops...
Journal ArticleDOI
Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial.
Enriqueta Felip,Leora Horn,Jyoti D. Patel,Hiroshi Sakai,Jürgen Scheele,Rolf Bruns,Paul K. Paik +6 more
TL;DR: It is shown that MET mutations causing exon 14 skipping produce c-Met receptors lacking a negative regulatory site, with the result that METΔex14 mutations are oncogenic drivers.
Journal ArticleDOI
Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)
Y. Cheng,Jiaojiao Zhou,Shaoyong Lu,Yinglin Zhang,J. Zhao,Hongming Pan,Yuh Min Chen,C.-F. Chian,Rolf Bruns,Andreas Johne,Jürgen Scheele,Y-L. Wu +11 more